Edition:
United Kingdom

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,554JPY
18 Dec 2018
Change (% chg)

¥-106 (-6.38%)
Prev Close
¥1,660
Open
¥1,652
Day's High
¥1,656
Day's Low
¥1,550
Volume
9,457,100
Avg. Vol
6,877,422
52-wk High
¥2,056
52-wk Low
¥1,380

Select another date:

Wed, Nov 28 2018

Astellas Pharma gets U.S. nod for blood cancer treatment

The U.S. Food and Drug Administration on Wednesday approved a blood cancer treatment from Japan's Astellas Pharma Inc, making it the first targeted therapy to treat patients with a certain mutation.

UPDATE 2-Astellas Pharma gets U.S. nod for blood cancer treatment

Nov 28 The U.S. Food and Drug Administration on Wednesday approved a blood cancer treatment from Japan's Astellas Pharma Inc, making it the first targeted therapy to treat patients with a certain mutation.

Astellas Pharma gets U.S. nod for blood cancer treatment

Nov 28 Japan's Astellas Pharma Inc on Wednesday received approval from the U.S. Food and Drug Administration for its blood cancer treatment, according to the regulator's website https://bit.ly/2SjB8CL.

Pfizer, Astellas revise two cancer drug trial protocols to speed up results

Drugmakers Pfizer Inc and Astellas Pharma Inc said on Wednesday they would change protocols for two late-stage trials testing prostate cancer drug Xtandi to speed up completion.

Pfizer, Astellas revise two cancer drug trial protocols to speed up results

Drugmakers Pfizer Inc and Astellas Pharma Inc said on Wednesday they would change protocols for two late-stage trials testing prostate cancer drug Xtandi to speed up completion.

Pfizer, Astellas revise two cancer drug trial protocols to speed up results

Aug 22 Drugmakers Pfizer Inc and Astellas Pharma Inc said on Wednesday they would change protocols for two late-stage trials testing prostate cancer drug Xtandi to speed up completion.

Select another date: